Forgot Password?
Return to Course Listing

CME: A critical appraisal of present and emerging management approaches to moderate to severe plaque psoriasis in adults: going beyond skin-deep

Activity Description / Statement of Need:

In this online, self-learning activity:

Psoriasis is a T-lymphocyte-mediated condition that is one of the most common immune-mediated inflammatory diseases in the North America and Europe. While subtypes of psoriasis have been described, plaque psoriasis, also known as psoriasis vulgaris, is the most common form. With a clinical presentation of red, scaly plaques on the skin that range in severity from minor, localized lesions to complete body coverage, it is also associated with inflammation of the joints and enthesial attachments and has potential of articular destruction—a complication known as psoriatic arthritis that affects up to 30% of those with the disease. Aside from its direct effects on the skin, it is also has associated with cardio-metabolic comorbidities and a heavy psychosocial burden.

Target Audience:

HCPs including: dermatologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with psoriasis.

Commercial Support Disclosure: This program is supported by an educational grant from Sun Pharmaceuticals. 

This activity is free of charge.

Release Date: June 07, 2024 -- Expiration Date: June 07, 2026

Faculty: April Armstrong, MD MPD


Faculty introduction, disclosures

Introduction content: review of plaque psoriasis 

  • Epidemiology statistics; patient quality-of-life and economic impact
  • Pathophysiology
  • Clinical features and presentation: distinguishing plaque psoriasis from other psoriasis subtypes
  • Common comorbidities and associated risks
  • Challenge of inadequate identification of and screening for primary and associated disease and risks

Treatment of moderate to severe plaque psoriasis 

  • Distinguishing moderate to severe disease
  • Present pharmacotherapy and real-world evidence
    • Oral therapy: phosphodiesterase-4 and TYK2 inhibitors
    • TNF-alpha inhibitors
    • IL-17 inhibitors
    • IL-23, IL-12, and related inhibitors
    • Roles of: folic acid antagonists, retinoids, and calcineurin inhibitors
    • Systemic therapy: the mainstay of treatment
    • Biosimilars considerations
    • The role of topical therapies
  • Precautions and considerations in specific populations, e.g., viral hepatitis, latent tuberculosis, pregnancy, cancer 
  • Minimizing adverse effects
  • Optimally managing comorbidities 
  • Adherence to therapy 
  • Patient case(s) 

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Identify the healthcare burdens associated with plaque psoriasis.
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of psoriasis.
  • Formulate a treatment plan for a patient with plaque psoriasis, including addressing comorbidities and risks.


ACCME Activity #202789195

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-24-013-H01-P. This is an Application (A)-type activity. ACPE credit release date: 6/30/2024; ACPE credit expiration date: 6/7/2026.

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.25 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.25 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.25 AMA PRA Category 1 Credit(s)™.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: April W. Armstrong, MD, MPH, Professor of Clinical Dermatology, Keck School of Medicine at USC, has received financial compensation from Abbvie, Amgen, BMS, Janssen, Mindera, Organon & Co, Sanofi and Takeda for speaker's bureau; ASLAN, Almirall, Amgen, Arcutis, Beiersdorf, BMS, Dermavant, EPI Health, Janssen, LEO Pharma, Mindera, Nimbus, Organon & Co, Sanofi, Sun Pharma, Takeda and Ventyx Biosciences for consulting;  Abbvie, ASLAN, BMS, Dermavant Sciences, Dermira, Lilly, Galderma, Incyte, Janssen, Leo Pharma, Meiji, Modernizing Medicine, Nimbus, Novartis, UCB, Ortho Dermatologics, Pfizer, Sanofi and Ventyx for research support; Boehringer Ingelheim and Parexel for Data Safety Monitoring Board.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Sun Pharmaceuticals. 


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Spotlight on actinic keratosis: updates in practice and treatment optimization

Recognition and management of epidermolysis bullosa: what the clinician needs to know

Present and novel approaches in the medical management of generalized pustular psoriasis: balancing out the therapeutic landscape

How implicit bias and culture competence shape the patient healthcare experience